Who Paid My Doc
Brian Burgess
Podiatrist, Foot & Ankle Surgery Naperville, IL Doctor of Podiatric Medicine
NPI 1285903146 CMS profile 239504
2940 Rollingridge Rd, Suite 102, Naperville, IL 60564
General payments
$488,082
Research payments
$0
Ownership & investment interest
$121,128
Through program year 2025, Brian Burgess of Naperville, IL is reported in the CMS Open Payments database as having received $488,082 across 368 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $121,128 across 5 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 99th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $103,935 | 119 | |
| 2024 | General | $67,667 | 100 | |
| 2023 | General | $276,297 | 52 | |
| 2022 | General | $14,539 | 27 | |
| 2021 | General | $18,754 | 30 | |
| 2020 | General | $1,840 | 13 | |
| 2019 | General | $5,051 | 27 | |
| 2025 | Ownership | $7,735 | 1 | |
| 2023 | Ownership | $7,735 | 1 | |
| 2022 | Ownership | $42,134 | 1 | |
| 2021 | Ownership | $37,510 | 1 | |
| 2020 | Ownership | $26,014 | 1 |
Beside peers
- Brian Burgess
- Podiatrist, Foot & Ankle Surgery median
- Middle half of Podiatrist, Foot & Ankle Surgery
- National median
In program year 2025, general payments to Brian Burgess were reported at $103,935. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.
Show as a table
| Year | Brian Burgess | Podiatrist, Foot & Ankle Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $5,051 | $389 | $118–$1,406 | $163 |
| 2020 | $1,840 | $191 | $62–$691 | $114 |
| 2021 | $18,754 | $329 | $104–$1,341 | $132 |
| 2022 | $14,539 | $419 | $125–$1,611 | $149 |
| 2023 | $276,297 | $377 | $128–$1,164 | $160 |
| 2024 | $67,667 | $394 | $134–$1,168 | $164 |
| 2025 | $103,935 | $424 | $139–$1,306 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
188
Drug cost
$3,756
Branded share of claims
40.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gemtesa Vibegron | Brand | 16 | $1,954 | |
| Gabapentin | Generic | 36 | $482 | |
| Captopril | Generic | 17 | $307 | |
| Ciclopirox | Generic | 14 | $299 | |
| Atorvastatin Calcium | Generic | 16 | $173 | |
| Sertraline Hcl | Generic | 16 | $171 | |
| Bupropion Xl Bupropion Hcl | Brand | 32 | $159 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 12 | $93 | |
| Methylprednisolone | Generic | 13 | $65 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 16 | $52 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 84 billing codesPaid by Medicare
$102,430
Medicare patients
338
Services billed
1,563
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 71% | |
| Arthritis | 66% | |
| Ischemic heart disease | 25% | |
| Diabetes | 23% | |
| Depression | 20% | |
| Osteoporosis | 19% | |
| Chronic kidney disease | 15% | |
| Atrial fibrillation | 12% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 58 | 288 | $207 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
368 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Podiatrist, Foot & Ankle Surgery in Illinois
Douglas Pacaccio
Podiatrist, Foot & Ankle Surgery · Rockford, IL
Lowell Weil
Podiatrist, Foot & Ankle Surgery · Mount Prospect, IL
Matthew Sorensen
Podiatrist, Foot & Ankle Surgery · Algonquin, IL
Edgardo Rodriguez Collazo
Podiatrist, Foot & Ankle Surgery · Chicago, IL
Patrick McEneaney
Podiatrist, Foot & Ankle Surgery · Cary, IL
Kyle Pearson
Podiatrist, Foot & Ankle Surgery · Morris, IL
Related records
Podiatrist, Foot & Ankle Surgery in Illinois
Practitioners in the same specialty and state, ranked by reported value.
All Podiatrist, Foot & Ankle Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Illinois
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.